April 15, 2025 a 12:00 pm
BMY: Fundamental Ratio Analysis - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, a leader in biopharmaceuticals, engages in discovering, developing, and marketing medicines globally. Despite recent challenges, its strong pipeline and focus on niche markets could offer growth opportunities.
Fundamental Rating
Bristol-Myers has a fundamental rating of 'C', indicating average performance with room for improvement.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical rating provides context on the company's evolving performance metrics.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-14 | 2 | 5 | 1 | 1 | 1 | 1 | 1 |
| Previous | 0 | 5 | 1 | 1 | 1 | 1 | 1 |
Analyst Price Targets
Analyst price targets suggest stable valuation expectations, with consensus reflecting a balanced outlook.
| High | Low | Median | Consensus |
|---|---|---|---|
| $61 | $61 | $61 | $61 |
Analyst Sentiment
Analyst sentiment towards Bristol-Myers is currently 'Hold', indicating mixed investor perspectives.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 14 | |
| Hold | 22 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Bristol-Myers Squibb possesses a strong footing in the healthcare sector with a variety of biopharmaceutical products catering to multiple diseases. Despite its current average performance ratings, the company has a robust product pipeline that holds promise for future growth. Mixed analyst sentiment reflects uncertainty, yet the stable price targets suggest a balanced investment outlook. The company faces opportunities in innovation but must navigate regulatory and competitive challenges to enhance its market position.